Back to Search
Start Over
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
- Source :
-
Nephrologie & therapeutique [Nephrol Ther] 2016 Dec; Vol. 12 (7), pp. 536-538. Date of Electronic Publication: 2016 Nov 04. - Publication Year :
- 2016
-
Abstract
- We report a case of sustained remission of a liver transplant patient infected with hepatitis C virus (HCV) genotype 1 undergoing hemodialysis treatment. Oral treatment regimen of the HCV infection consists of a combination of sofosbuvir 400 mg after each hemodialysis session and daclatasvir 60 mg daily, for a period of 3 months. Laboratory testing indicate that the combination regimen was well-tolerated with no sign of drug-drug interaction. Confirmation of these clinical observations in large clinical studies may help improve morbidity and decrease mortality outcome in patients infected with HCV and undergoing hemodialysis treatment.<br /> (Copyright © 2016 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.)
- Subjects :
- Carbamates
Carcinoma, Hepatocellular complications
Carcinoma, Hepatocellular surgery
Drug Therapy, Combination
Hepatitis C complications
Humans
Liver Cirrhosis complications
Liver Cirrhosis etiology
Liver Cirrhosis surgery
Liver Cirrhosis virology
Liver Neoplasms complications
Liver Neoplasms surgery
Male
Middle Aged
Pyrrolidines
Renal Insufficiency, Chronic complications
Renal Insufficiency, Chronic therapy
Risk Factors
Treatment Outcome
Valine analogs & derivatives
Antiviral Agents therapeutic use
Hepatitis C drug therapy
Imidazoles therapeutic use
Liver Transplantation
Renal Dialysis
Sofosbuvir therapeutic use
Subjects
Details
- Language :
- French
- ISSN :
- 1872-9177
- Volume :
- 12
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Nephrologie & therapeutique
- Publication Type :
- Academic Journal
- Accession number :
- 27825643
- Full Text :
- https://doi.org/10.1016/j.nephro.2016.05.010